Benzinga's Microcap Movers for Thursday June 21, 2012
Below are highlights from Benzinga's daily coverage of small cap and microcap securities making big moves:
Phototron Holdings (PHOT), the Woodland Hills, CA manufacturer of indoor light emitting diode grow lights and LED grow panels, rose 208% Thursday on 4.5 times the average daily volume.
An article appearing on seattlepi.com on Wednesday, discussed how the company's hydroponic growing tools could be used by pateients to grow their own medical marijuana.
Phototron Holdings closed at $0.11 on Thursday.
Shares of Aerius International (AERS), the Las Vegas, NV cell phone engineering and design company, rose 696% Thursday on 111 times the average daily volume.
There was no specific news to account for the move and a company spokesperson was not available for comment.
Aerius International closed at $0.02 on Thursday.
Shares of Chelsea Therapeutics (NSDAQ: CHTP), the Charlotte, NC pharmaceutical company, rose 19.08% Thursday on 4 times the average daily volume.
Chelsea Therapeutics announced Thursday results from an integrated dataset of two phase 3 studies, Study 301 and Study 302, which showed that patients treated with Northera (droxidopa) experienced improvements in their symptoms of Neurogenic Orthostatic Hypotension (also known as NOH or Neurogenic OH) as measured by the Orthostatic Hypotension Questionnaire composite score (p=0.001) and a number of individual symptoms, including dizziness (p=0.004). The results, which include data from over 250 patients with symptomatic Neurogenic OH and diagnoses of Parkinson's disease, multiple system atrophy, pure autonomic failure, dopamine beta hydroxylase deficiency or nondiabetic autonomic neuropathy, were presented by Christopher Mathias, MD at the 16th International Congress of Parkinson's Disease and Movement Disorders in Dublin, Ireland.
Chelsea Therapeutics closed at $1.56 on Thursday.
The information in this article is taken from public sources, press releases, and websites that cannot always be verified. Please note that investing in microcap stocks is highly speculative. The companies mentioned here are for information purposes only. Benzinga makes no claim as to the suitability of these stocks as an investment. Neither Benzinga nor its staff recommend that you buy, sell, or hold any security. We do not offer investment advice, personalized or otherwise. Benzinga recommends that you conduct your own due diligence and consult a certified financial professional for personalized advice about your financial situation.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.